Refine
Has Fulltext
- yes (10)
Is part of the Bibliography
- yes (10)
Document Type
- Journal article (9)
- Conference Proceeding (1)
Language
- English (10)
Keywords
- PRRT (4)
- theranostics (4)
- CXCR4 (2)
- multiple myeloma (2)
- neuroendocrine tumor (2)
- somatostatin receptor (2)
- 177Lu (1)
- 177Lu-DOTATATE (1)
- 177Lu-DOTATOC (1)
- C-X-C motif chemokine receptor 4 (1)
- Combination (1)
- DOTA-EB-TATE (1)
- EBRT (1)
- MAG3 (1)
- Medizin (1)
- Meningioma (1)
- Neuroendocrine Tumor (1)
- PET (1)
- Peptide receptor radionuclide therapy (1)
- Positronen-Emissions-Tomografie (1)
- Radiotherapy (1)
- SSTR-PET (1)
- [177Lu]PentixaTher (1)
- [68Ga]DOTATOC (1)
- [68Ga]PentixaFor (1)
- [90Y]PentixaTher (1)
- acute renal failure (1)
- adrenocortical carcinoma (1)
- adsorption (1)
- biokinetics (1)
- combination (1)
- endoradiotherapy (1)
- evans blue (1)
- intraindividual comparison (1)
- iodine contrast (1)
- medicine (1)
- papillary thyroid carcinoma (PTC) (1)
- peptide receptor (1)
- quantification (1)
- radioiodine (1)
- radionuclide therapy (1)
- renal scintigraphy (1)
- sarcoidosis (1)
- selpercatinib (1)
- somatostatin receptors (1)
- sorbents (1)
- thyroid carcinoma (TC) (1)
Institute
- Klinik und Poliklinik für Nuklearmedizin (9)
- Medizinische Klinik und Poliklinik II (3)
- Medizinische Klinik und Poliklinik I (2)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (1)
- Institut für Klinische Transfusionsmedizin und Hämotherapie (1)
- Klinik und Poliklinik für Strahlentherapie (1)
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 701983 (2)
Purpose
The radiolabelled somatostatin analogue [\(^{177}\)Lu]Lu-DOTA-EB-TATE binds to albumin via Evans blue, thereby increasing the residence time in the blood and potentially allowing more therapeutic agent to be absorbed into the target tissue during peptide receptor radionuclide therapy. It was tested in selected patients whether the substance is superior to [\(^{177}\)Lu]Lu-DOTA-TOC.
Methods
Activity kinetics in organs and tumours after [\(^{177}\)Lu]Lu-DOTA-EB-TATE and [\(^{177}\)Lu]Lu-DOTA-TOC were compared intraindividually in five patients with progressive somatostatin receptor-positive disease scheduled for radionuclide therapy.
Resuluts
In comparison to [\(^{177}\)Lu]Lu-DOTA-TOC, tumour doses per administered activity were higher for [\(^{177}\)Lu]Lu-DOTA-EB-TATE in 4 of 5 patients (median ratio: 1.7; range: 0.9 to 3.9), kidney doses (median ratio: 3.2; range: 1.6 to 9.8) as well as spleen doses (median ratio: 4.7; range 1.2 to 6.2) in all patients, and liver doses in 3 of 4 evaluable patients (median ratio: 4.0; range: 0.7 to 4.9). The tumour to critical organs absorbed dose ratios were higher after [\(^{177}\)Lu]Lu-DOTA-TOC in 4 of 5 patients.
Conclusions
Prior to a treatment with [\(^{177}\)Lu]Lu-DOTA-EB-TATE, it should be assessed individually whether the compound is superior to established substances.